Gastrointestinal bleeding risk of selective serotonin reuptake inhibitors by level of kidney function: A population-based cohort study. by Iwagami, Masao et al.
Iwagami, M; Tomlinson, LA; Mansfield, KE; Douglas, IJ; Smeeth, L;
Nitsch, D (2018) Gastrointestinal bleeding risk of selective serotonin
reuptake inhibitors by level of kidney function: a population-based
cohort study. British journal of clinical pharmacology. ISSN 0306-
5251 DOI: https://doi.org/10.1111/bcp.13660
Downloaded from: http://researchonline.lshtm.ac.uk/4647987/
DOI: 10.1111/bcp.13660
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
ORIGINAL ARTICLE
Gastrointestinal bleeding risk of selective
serotonin reuptake inhibitors by level
of kidney function: A population-based
cohort study
CorrespondenceMasao Iwagami, MD,MPH,MSc, Department of Non-Communicable Disease Epidemiology, London School of Hygiene
and Tropical Medicine, London, UK. Keppel Street, London, WC1E 7HT, UK. Tel.: +44 (0)20 7636 8636; Fax: +44 (0)20 7436 5389;
E-mail: masao.iwagami@lshtm.ac.uk
Received 27 November 2017; Revised 9 May 2018; Accepted 30 May 2018
Masao Iwagami , Laurie A. Tomlinson, Kathryn E. Mansﬁeld, Ian J. Douglas, Liam Smeeth and
Dorothea Nitsch
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Keywords additive interaction, gastrointestinal bleeding, kidney function, multiplicative interaction, selective serotonin reuptake
inhibitor
AIM
To estimate the risk of gastrointestinal (GI) bleeding associated with serotonin reuptake inhibitors (SSRIs) by level of kidney
function.
METHODS
We conducted a cohort study using the Clinical Practice Research Datalink linked to Hospital Episode Statistics. We identiﬁed
patients with chronic kidney disease (CKD; estimated glomerular ﬁltration rate <60 ml min–1 1.73 m–2 for ≥3 months), and a
comparison group of patients without it. Patients with CKDwere further classiﬁed as stage 3a (eGFR 45–59ml min–1 1.73m–2), 3b
(30–44 ml min–1 1.73 m–2) and 4/5 (<30 ml min–1 1.73 m–2). We excluded prevalent SSRI users at cohort entry. Exposure was
time-dependent SSRI prescription and outcome was ﬁrst hospitalization for GI bleeding. We estimated adjusted rate ratio (aRR)
and rate difference (aRD) of GI bleeding comparing periods with and without SSRI prescription at each level of kidney function.
RESULTS
The aRRs and aRDs were: (i) no CKD (n = 202 121) aRR: 1.66 (95%CI 1.37–2.01), aRD: 2.0/1000 person–years (5.5 vs. 3.5/1000
person–years in period with and without SSRIs); (ii) CKD stage 3a (n = 153 316) aRR: 1.86 (1.62–2.15), aRD: 4.2/1000
person–years (8.3 vs. 4.1/1000 person–years); (iii) CKD stage 3b (n = 46 482) aRR: 1.61 (1.27–2.04), aRD: 4.8/1000 person–years
(9.9 vs. 5.1/1000 person–years); and (iv) CKD stage 4/5 (n = 11 197) aRR: 1.84 (1.14–2.96), aRD: 7.9/1000 person–years (15.3 vs.
7.4/1000 person–years). While there was no evidence of increase in the aRR (P = 0.922), there was strong evidence that the aRD
increased as kidney function deteriorated (P = 0.001).
CONCLUSIONS
While the relative risk was constant, the excess risk of GI bleeding associated with SSRIs markedly increased among patients with
decreased kidney function.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Previous studies have suggested that use of selective serotonin reuptake inhibitors (SSRIs) is associated with increased risk
of gastrointestinal (GI) bleeding.
• Patients with decreased kidney function are known to have an increased risk of bleeding.
• However, no study has investigated the risk of GI bleeding associated with SSRIs at different levels of kidney function.
WHAT THIS STUDY ADDS
• We estimated the relative and absolute risks of GI bleeding associated with SSRI prescription at different levels of kidney
function.
• While the relative risk of GI bleeding associated with SSRIs was similar at different levels of kidney function, the excess
risk of GI bleeding associated with SSRIs increased as kidney function deteriorated.
• Therefore, we recommend careful use of SSRIs in patients with decreased kidney function.
Introduction
Chronic kidney disease (CKD) is a common condition in the
community [1], and is independently associated with
increased risk of bleeding in operative and nonoperative
settings [2–4]. Gastrointestinal (GI) bleeding is the most com-
mon manifestation of bleeding [5].
Patients with CKD are known to have increased
prevalence of mental-health problems such as depression
and anxiety [6, 7]. Accordingly, our recent study suggested
that patients with CKD (not on dialysis) have antidepressants
prescribed more frequently than patients without it [8].
Selective serotonin reuptake inhibitors (SSRIs) are currently
recommended as the ﬁrst choice of drug therapy for
depressed patients [9]. The number of SSRI prescriptions has
been steadily increasing in the UK and US [10, 11].
There is concern regarding the bleeding risk associated
with SSRIs, because SSRIs block serotonin reuptake in
platelets and inhibit platelet aggregation [12, 13]. A number
of studies have shown an association between the use of SSRIs
and GI bleeding [14–24]. However, none of these studies
focused on the risk of GI bleeding associated with SSRIs
among patients with CKD. SSRI-associated GI bleeding is of
particular concern among patients with CKD [25, 26],
because: (i) CKD is itself a risk factor for GI bleeding [3]; and
(ii) SSRIs may accumulate in patients with CKD due to
reduced renal clearance and altered pharmacokinetics [27].
Despite these concerns, the absolute and relative risks of
GI bleeding associated with SSRI use amongst patients with
reduced kidney function have not been quantiﬁed. We there-
fore undertook a population-based study addressing this
question in a large UK primary care database.
Methods
Data sources
The Clinical Practice Research Datalink (CPRD) is a database
of routinely recorded primary care electronic health record
data from 7% of the UK population [28]. The CPRD includes
the following information: patient demographics, coded di-
agnoses (Read codes), prescriptions, laboratory test results,
and referrals recorded by general practitioners (GPs). The
CPRD is linked with other resources, including Hospital
Episode Statistics (HES), Ofﬁce for National Statistics
mortality data and Index of Multiple Deprivation data. HES
contains details of all hospital admissions to the National
Health Service hospitals in England, and consists of primary
and subsidiary diagnoses recorded during admission using
the 10th revision of International Classiﬁcation of Disease
(ICD-10) codes [29]. Currently, around 400 general practices
in CPRD (accounting for 75% of general practices in CPRD
in England) have agreed to linkage with HES data for research
purposes. Study approval was obtained from the ethics
committee of the London School of Hygiene and Tropical
Medicine (reference: 9196) and the Independent Scientiﬁc
Advisory Committee, which oversees research involving
CPRD data (Protocol 15_219R).
Study cohort
We used a matched cohort including 242 349 patients with
CKD and 242 349 patients without it, which was established
in our previous study for the prevalence and incidence of an-
tidepressant prescribing by CKD status [8]. Using HES-linked
CPRD between 1 April 2004 and 31March 2014, we ﬁrst iden-
tiﬁed adult patients with CKD (not on renal replacement
therapy) based on two consecutive measurements of eGFR
<60 ml min–1 1.73 m–2 for ≥3 months [30] (Figure 1). Esti-
mated GFR was calculated from serum creatinine values re-
corded in CPRD, using the Chronic Kidney Disease
Epidemiology Collaboration equation [31]. Patients were eli-
gible for cohort entry from the latest of: 1 April 2004, 1 year
after practice registration (to allow GPs to record the past
medical history of newly registered patients) or the date the
patient’s general practice reached CPRD’s data quality stan-
dards [28]. Patients entered the cohort on the date when they
ﬁrst satisﬁed the CKD deﬁnition (i.e. second eGFR
<60 ml min–1 1.73 m–2) after meeting the eligibility criteria.
We then identiﬁed a comparison group of patients without
known CKD from the remaining HES-linked CPRD popula-
tion. To establish a balanced comparison group in terms of
basic patient characteristics, we randomly selected a patient
without known CKD with the same age, sex, general practice
and calendar time (i.e. same date of cohort entry) as a patient
with CKD.
Patients with CKD were further classiﬁed according to
eGFR on the date of cohort entry: CKD stage 3a (eGFR
45–59 ml min–1 1.73 m–2), stage 3b (30–44 ml min–1 1.73 m–2),
and stage 4 or 5 (<30 ml min–1 1.73 m–2) [30]. CKD stage
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was regarded as constant (i.e. non-time updated) during
follow-up. We then excluded the following patients:
(i) prevalent SSRI users (GI bleeding could occur shortly af-
ter SSRI initiation [17], therefore inclusion of prevalent SSRI
users with drug tolerance may cause bias [32]); (ii) those
with a history of GI bleeding (to capture new-onset GI
bleeding more likely to be related to drug exposure); and
(iii) those with missing values of smoking status and body
mass index (BMI).
Exposure and outcome
SSRIs are frequently started and stopped in clinical care [33].
Our exposure of interest was therefore time-dependent pre-
scription of SSRIs. The duration of each prescription was esti-
mated by dividing the total number of tablets prescribed by
the number of tablets to be taken each day (daily dose). When
the daily dose or total number of tablets was missing (9.6% of
the records), we imputed the median prescription duration
(28 days). We assumed that patients were continuously ex-
posed to SSRIs if there were no gaps of more than 30 days be-
tween the end of one prescription and the start of the next (to
allow potential medication stockpiling or prescribing in sec-
ondary care) [14]. If there was no subsequent prescription of
SSRIs, we considered patients could be inﬂuenced by the ef-
fect of SSRIs until 30 days after the end of the prescription.
Thus, each episode of SSRI treatment started at the ﬁrst SSRI
prescription (as a new treatment episode) and continued un-
til 30 days after a break in continuous prescribing of 30 days
(or more). A patient could contribute multiple episodes of
SSRI treatment during follow-up. In sensitivity analyses, we
changed our assumption of a 30-day duration of periods
between prescriptions and washout periods to 60 days and
90 days.
The outcome was the ﬁrst hospitalization with a primary
diagnosis of GI bleeding, based on a list of ICD-10 codes
(Appendix S1). Patients were followed up until the earliest
of: the outcome of interest, initiation of renal replacement
therapy, death, change of general practice, last data collection
from the practice or 31 March 2014.
Covariates
We considered the following potential confounders in the as-
sociation between SSRI prescription and GI bleeding [14–24]:
age and sex; ethnicity; socio-economic status; BMI; smoking
status; comorbidities (diabetes mellitus, chronic liver disease,
congestive heart failure, cancer, and rheumatoid arthritis);
and prescribed drugs including anticoagulants, antiplatelet
drugs (including aspirin), nonsteroidal anti-inﬂammatory
drugs (excluding aspirin), oral corticosteroids, and acid-
suppressing agents. We classiﬁed patients with no record of
ethnicity as white, consistent with previous UK studies [34].
Socioeconomic status was assigned at an individual level,
using quintiles of 2010 Ofﬁce for National Statistics estimates
of the Index of Multiple Deprivation (a composite area-level
marker of deprivation) [35]. Smoking status and BMI were
assigned using the data recorded closest to cohort entry and
assumed to be constant during follow-up. We deﬁned each
comorbidity as present or absent based on recording of a rel-
evant diagnostic code in CPRD on the day of, or prior to, co-
hort entry. For prescribed drugs, we used the same strategy
as SSRIs by regarding them as time-dependent confounding
factors.
Statistical analysis
We described baseline patient characteristics by level of kid-
ney function. We showed the length of time people received
an SSRI prescription and the time without, at each level of
kidney function (i.e. no CKD, CKD stage 3a, stage 3b, and
stage 4 or 5). We also showed the number of ﬁrst hospitaliza-
tions due to GI bleeding, providing the crude incidence rate
of the outcome by SSRI prescription status at each level of kid-
ney function.
We conducted prespeciﬁed analyses using two common
measures of effect to understand the GI bleeding risk
Figure 1
Flow chart for selecting the study participants. BMI = body mass index, CKD = chronic kidney disease, CPRD = Clinical Practice Research Datalink,
GI = gastrointestinal, HES = Hospital Episode Statistics, RRT = renal replacement therapy, SSRI = selective serotonin reuptake inhibitor
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associated with SSRIs: risk ratio and risk difference [36]. First,
we estimated an adjusted rate ratio for GI bleeding when pre-
scribed an SSRI, compared to time not prescribed an SSRI,
using multiplicative Poisson regression analyses. Multiplica-
tive models assume that the risk of the outcome is multiplied
by different risk factors. We established multiplicative
Poisson models for hospitalization due to GI bleeding com-
paring periods with and without SSRI prescription at each
level of kidney function, ﬁrst adjusting for age and sex; and
then further adjusting for ethnicity, socioeconomic status,
BMI, smoking status, comorbidities, and prescribed drugs.
We then conducted a test for multiplicative interaction (ef-
fect modiﬁcation) between SSRI prescription and kidney
function in the fully-adjusted model. A signiﬁcant multipli-
cative interaction would suggest that the risk ratio (period
with vs. without SSRI prescription) is different at different
levels of kidney function. We estimated a multiplicative in-
teraction P-value for trend, using the log-likelihood ratio test
comparing the Poisson models with and without an interac-
tion term between SSRI prescription status and kidney
function.
Next, we estimated an adjusted rate difference (between
period with and without SSRI prescription) for GI bleeding
at each level of kidney function and tested whether the ad-
justed rate difference increased as kidney function deterio-
rated, using additive Poisson regression analyses. Additive
models assume that risk differences from different risk factors
are added together to estimate the risk of outcome [37] and,
therefore, can directly test an additive interaction [38]. We
established a fully-adjusted additive Poisson model for GI
bleeding (Appendix S2 for more detail). We then calculated
an adjusted incidence rate with or without SSRI prescription
at each level of kidney function, by applying the average ef-
fect of each covariate on the risk of GI bleeding in the study
population in the fully-adjusted additive Poisson model
(Appendix S3 for more detail). Thus, the adjusted incidence
rate in each group stratiﬁed by SSRI prescription status and
level of kidney function represents a hypothetical incidence
rate if the confounders (e.g. diabetes) are equally distributed
between the groups. We then estimated an adjusted rate dif-
ference between the period with and without SSRI prescrip-
tion at each level of kidney function. Finally, we conducted
a test for additive interaction between SSRI prescription sta-
tus and kidney function. A signiﬁcant additive interaction
would suggest that the risk difference (between period with
and without SSRI prescription) is different at different levels
of kidney function. We calculated an additive interaction
P-value for trend, using the log-likelihood ratio test compar-
ing the models with and without an interaction term be-
tween SSRI prescription and kidney function.
All the data management and statistical analyses were
conducted using STATA version 14 (Stata Corp, Texas). A
P-value of < 0.05 was inferred as statistically signiﬁcant.
Subgroup analysis
We conducted posthoc subgroup analyses (separately) by
SSRI dose and receptor afﬁnity in the fully-adjusted multi-
plicative Poisson regression models. Based on the deﬁned
daily dose (DDD) of each SSRI (20 mg day–1 for citalopram,
10 mg day–1 for escitalopram, 20 mg day–1 for ﬂuoxetine,
100 mg day–1 for ﬂuvoxamine, 20 mg day–1 for paroxetine
and 50 mg day–1 for sertraline) [39], we dichotomized the pe-
riods of SSRI prescription into two categories: periods of low
dose (i.e. smaller daily dose thanDDD), and periods of normal
or high dose (i.e. same as or higher dose than DDD). Low and
normal/high dose periods were compared to periods without
SSRI prescription. For the serotonin receptor afﬁnity sub-
group analysis, we divided the periods of SSRI prescription
into two categories [17]: SSRIs with intermediate afﬁnity to
the serotonin receptor (including citalopram, ﬂuvoxamine
and escitalopram), and thosewithhigh afﬁnity (includingﬂu-
oxetine, paroxetine and sertraline).
Results
Among 4 070 806 adult patients without renal replacement
therapy [median age 39 years (interquartile range, IQR 27–
56), male 48.8%] registered in HES-linked CPRD between
2004 and 2014, we identiﬁed 264 628 patients with CKD [me-
dian age 77 years (IQR 71–83), male 38.7%]. Of those with
CKD, 242349 [92%; median age 76 years (IQR 70–82), male
39.3%] were matched with a patient without known CKD
who had the same age, sex, general practice, and same date
of cohort entry (Figure 1). After excluding (i) prevalent SSRI
users at cohort entry, (ii) those with a history of GI bleeding
and (iii) those withmissing values of BMI and smoking status,
there were 413 116 study participants including 202 121 pa-
tients without known CKD, 153316 patients with CKD stage
3a, 46 482 patients with CKD stage 3b, and 11197 patients
with CKD stage 4 or 5. The number of patients exposed to
SSRIs during the study period was 16 911 (4.1% of patients
without known CKD), 18 545 (12.1% of patients with CKD
stage 3a), 5803 (12.5% of patients with CKD stage 3b) and
1063 (9.5% of patients with CKD stage 4 or 5), respectively.
The patterns of prescribed SSRI and dose were similar at differ-
ent levels of kidney function (Appendix S4). Patients with
CKD were more likely to have a lower socioeconomic status,
had a higher prevalence of many comorbidities and were
more likely to be prescribedmedications at baseline (Table 1).
In the total cohort, there were 7249 ﬁrst hospitalizations
due to GI bleeding during total follow up of 1 801 316
person–years [median follow-up length 4.0 years (IQR 1.7–
6.8 years)]. Crude incidence rate for GI bleeding was generally
higher among patients with more advanced CKD stages, and
was higher during the period with SSRI prescription than the
period without SSRI prescription at each level of kidney func-
tion (Table 2).
In the fully-adjusted multiplicative Poisson regression
model, the adjusted rate ratio (period with vs. without SSRI
prescription) was 1.66 [95% conﬁdence interval (CI),
1.37–2.01] among patients with no CKD, 1.86 (1.62–2.15)
among patients with CKD stage 3a, 1.61 (1.27–2.04) among
patients with CKD stage 3b, and 1.84 (1.14–2.96) among pa-
tients with CKD stage 4 or 5 (Table 2). A test for multiplicative
interaction in the fully-adjusted multiplicative Poisson
model gave a P-value for trend of 0.922, suggesting that there
is no evidence of increased relative risk of GI bleeding related
to SSRI prescription among patients with more advanced
CKD stages.
SSRI and GI bleeding by kidney function
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Table 1
Baseline characteristics of patients by level of kidney function
Patients with no
CKD (N = 202 121)
Patients with CKD
stage 3a (N = 153 316)
Patients with CKD
stage 3b (N = 46 482)
Patients with CKD s
tage 4/5 (N = 11 197)
n (%) n (%) n (%) n (%)
Age (years):
<65 26 464 (13.1) 21 437 (14.0) 3835 (8.3) 1565 (14.0)
65–74 63 882 (31.6) 52 388 (34.2) 10 676 (23.0) 2292 (20.5)
75–84 86 433 (42.8) 63 509 (41.4) 22 241 (47.9) 4653 (41.6)
≥85 25 342 (12.5) 15 982 (10.4) 9730 (20.9) 2687 (24.0)
Sex (male) 81 861 (40.5) 62 828 (41.0) 17 928 (38.6) 5044 (45.1)
Ethnicity:
White/not recorded 198 618 (98.3) 150 538 (98.2) 45 673 (98.3) 10 855 (97.0)
South Asian 1657 (0.8) 1552 (1.0) 444 (1.0) 164 (1.5)
Black 1089 (0.5) 687 (0.5) 194 (0.4) 121 (1.1)
Other ethnicity 757 (0.4) 539 (0.4) 171 (0.4) 57 (0.5)
Socioeconomic status:
1 (least deprived) 47 706 (23.6) 34 538 (22.5) 9552 (20.6) 2083 (18.6)
2 51 542 (25.5) 38 806 (25.3) 11 362 (24.4) 2567 (22.9)
3 41 977 (20.8) 31 792 (20.7) 9749 (21.0) 2394 (21.4)
4 35 234 (17.4) 27 911 (18.2) 8860 (19.1) 2318 (20.7)
5 (most deprived) 25 662 (12.7) 20 269 (13.2) 6959 (15.0) 1835 (16.4)
Body mass index (kg m–2):
<18.5 6105 (3.0) 2590 (1.7) 1193 (2.6) 338 (3.0)
18.5–25 81 294 (40.2) 46 340 (30.2) 15 342 (33.0) 3898 (34.8)
≥25 76 780 (38.0) 61 231 (39.9) 17 618 (37.9) 3997 (35.7)
≥30 37 942 (18.8) 43 155 (28.2) 12 329 (26.5) 2964 (26.5)
Smoking status:
Non-smoker 74 991 (37.1) 48 878 (31.9) 15 173 (32.6) 3636 (32.5)
Ex-smoker 96 231 (47.6) 86 433 (56.4) 25 597 (55.1) 6056 (54.1)
Current-smoker 30 899 (15.3) 18 005 (11.7) 5712 (12.3) 1505 (13.4)
Comorbidities:
Diabetes mellitus 21 908 (10.8) 33 463 (21.8) 11 082 (23.8) 3205 (28.6)
Chronic liver disease 963 (0.5) 1068 (0.7) 348 (0.8) 95 (0.9)
Congestive heart failure 5873 (2.9) 10 700 (7.0) 6607 (14.2) 2344 (20.9)
Cancer 40 291 (19.9) 32 872 (21.4) 11 240 (24.2) 2864 (25.6)
Rheumatoid arthritis 3571 (1.8) 3667 (2.4) 1156 (2.5) 276 (2.5)
Prescribed drugs (at cohort entry)a:
Antiplatelet drugs 46 531 (23.0) 55 929 (36.5) 19 082 (41.1) 4655 (41.6)
Anticoagulants 6672 (3.3) 10 120 (6.6) 3882 (8.4) 904 (8.1)
Non-steroidal anti-inﬂammatory drugs 14 084 (7.0) 14 245 (9.3) 4810 (10.4) 933 (8.3)
Oral corticosteroids 5343 (2.6) 6319 (4.1) 2432 (5.2) 673 (6.0)
Acid-suppressing agents 32 476 (16.1) 37 370 (24.4) 12 803 (27.5) 3472 (31.0)
CKD, chronic kidney disease.
aprescribed drugs were time-updated during the follow-up.
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In the fully-adjustedadditivePoissonmodel (AppendixS2),
we applied the average effect of each covariate on the risk of
GI bleeding in the study population (Appendix S3) to esti-
mate adjusted rates for GI bleeding by SSRI prescription status
at each level of kidney function (Figure 2). The adjusted rate
difference increased from 2.0/1000 person–years among
patients with no CKD (due to the adjusted rate of 5.5 vs.
3.5/1000 person–years in period with and without SSRI
prescription, respectively), to 4.2/1000 person–years among
patients with CKD stage 3a (8.3 vs. 4.1/1000 person–years),
to 4.8/1000 person–years among patients with CKD stage 3b
(9.9 vs. 5.1/1000 person–years), and to 7.9/1000 person–years
among patients with CKD stage 4/5 (15.3 vs. 7.4/1000
person–years). A test for additive interaction gave a P-value
for trend of 0.001, suggesting that there is strong evidence
of increased risk difference of GI bleeding related to SSRI pre-
scription as kidney function deteriorates.
In sensitivity analyses, the results were similar after
changing our assumption about the length of periods be-
tween prescriptions and washout periods of SSRI prescription
from 30 days to 60 and 90 days (Appendix S5).
In subgroup analyses, at each level of kidney function, the
95% CIs of adjusted rate ratios for periods with low and
normal/higher dose of SSRIs largely overlapped, as did the
CIs for periods exposed to SSRIs with intermediate afﬁnity
and those for SSRIs with high afﬁnity (Appendices S6 and S7).
Discussion
In this large population-based study, we demonstrated that
the relative risk of GI bleeding associated with SSRI exposure
(i.e. the fully-adjusted rate ratio between periods with and
without SSRI prescription) was around 1.7 regardless of kid-
ney function. However, we showed strong evidence that the
excess risk of GI bleeding (i.e. the fully-adjusted rate
difference between periods with and without SSRI exposure)
increased substantially as renal function declined;
ranging from 2.0/1000 person–years among patients with
no CKD to 7.9/1000 person–years among patients with CKD
stage 4/5.
Table 2
Crude incidence rate by selective serotonin reuptake inhibitor prescription status and adjusted rate ratio for the ﬁrst hospitalization due to gastro-
intestinal bleeding among patients with different levels of kidney function
Length of follow-up
(person–years)
Number of
outcomes
Crude incidence
rate (95%CI)
(/1000 person–years)
Age- and sex-adjusted
rate ratio (95% CI)
Fully-adjusteda
rate ratio (95% CI)
Total in the cohort
(N = 413 116)
1 801 316 7249 4.0 (3.9–4.1) - -
Among patients with no
CKD (N = 202 121):
Period without SSRI
prescription
808 125 2413 3.0 (2.9–3.1) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
19 152 110 5.7 (4.8–6.9) 1.98 (1.64–2.40) 1.66 (1.37–2.01)
Among patients with CKD
stage 3a (N = 153 316):
Period without SSRI
prescription
709 140 2962 4.2 (4.0–4.3) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
23 311 204 8.8 (7.6–10.0) 2.16 (1.88–2.49) 1.86 (1.62–2.15)
Among patients with CKD
stage 3b (N = 46 482):
Period without SSRI
prescription
198 735 1174 5.9 (5.6–6.3) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
6904 73 10.6 (8.4–13.3) 1.85 (1.46–2.34) 1.61 (1.27–2.04)
Among patients with CKD
stage 4/5 (N = 11 197):
Period without SSRI
prescription
34 894 295 8.5 (7.5–9.5) 1 (Ref.) 1 (Ref.)
Period with SSRI
prescription
1055 18 17.1 (10.8–27.1) 2.10 (1.30–3.38) 1.84 (1.14–2.96)
CI = conﬁdence interval, CKD = chronic kidney disease, SSRI = selective serotonin reuptake inhibitor.
aadjusted for age, sex, ethnicity, socio-economic status, body mass index, smoking status, comorbidities (diabetes mellitus, chronic liver disease,
congestive heart failure, cancer, and rheumatoid arthritis), and prescribed drugs (antiplatelet drugs, anticoagulants, non-steroidal anti-inﬂammatory
drugs, oral corticosteroids, and acid-suppressing agents).
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To our knowledge, this is the ﬁrst study examining the
risk of GI bleeding associated with SSRIs at different levels
of kidney function, and testing multiplicative and additive
interactions between SSRI prescription and kidney func-
tion. The relative risk of GI bleeding due to SSRI prescrip-
tion found in our study (around 1.7 regardless of kidney
function) was consistent with that of a recent
meta-analysis [13], which found a pooled relative risk of
GI bleeding associated with SSRI use of 1.55 (95% CI,
1.35–1.78) across 22 studies. However, none of the studies
included in the meta-analysis estimated an adjusted rate
difference between patients (or periods of time) with and
without SSRI prescription. This additional information is
extremely useful. Because there are likely to be many con-
founders between patients (or periods of time) with and
without SSRI prescriptions, a crude rate difference of the
outcome between the groups may be substantially different
from that attributable to the medication.
There are several reasons for being concerned about a
potential ampliﬁcation of the relative risk of GI bleeding as-
sociated with SSRIs among patients with decreased kidney
function. Firstly, there is some evidence that renal clearance
of SSRIs is decreased and their elimination half-life is
prolonged in patients with decreased kidney function [27].
Other aspects of pharmacokinetics, such as liver metabo-
lism and plasma protein binding, may also be altered
among patients with CKD [40]. Furthermore, polypharmacy
is common among patients with CKD [41], and, therefore,
a potential drug–drug interaction between SSRIs and other
drugs could increase the bleeding risk of SSRIs in the CKD
population. However, in our real-world data, the relative
risk of SSRIs was found to be similar irrespective of baseline
kidney function, with no evidence of multiplicative
interaction.
However, there was strong evidence that the excess risk of
GI bleeding associated with SSRI exposure increased substan-
tially as kidney function declined. This represents a public-
health interaction [42]; a larger absolute risk increase means a
larger number of patients experiencing the outcome, suggest-
ing a larger public-health burden in the population. Even
when the relative risk of a drug is constant across subgroups,
the absolute number of patients who experience an adverse
effect of the drug will be larger in a group with a high risk of
the outcome. We formally tested if this was the case in our
study by adjusting for comorbidities and medications, the
distribution of which was different between the groups at
each level of kidney function. Therefore, the observed graded
increase in the excess risk of GI bleeding (i.e. adjusted rate dif-
ference between periods with and without SSRIs) can be as-
cribed to CKD itself, rather than conditions associated with
CKD (e.g. diabetes, antiplatelet use). The pathophysiology
of bleeding tendency in patients with CKD is multifactorial,
including platelet dysfunction and vessel wall damage [43].
In addition, patients with CKD are more likely to have ante-
cedents of GI bleeding, such as peptic ulcer disease [44].
We need to acknowledge several limitations of the study.
Firstly, we deﬁned CKD using strict criteria based on two se-
rum creatinine results in CPRD, and identiﬁed a comparison
group sampled from the rest of the general population.
However, creatinine testing in primary care is not universal
(currently, this is recommended and incentivized for people
at risk of CKD [45, 46]), and therefore we may have
misclassiﬁed some patients with unmeasured CKD into the
comparison group. Nevertheless, because the prevalence of
CKD (eGFR <60 ml min–1 1.73 m–2) identiﬁed in CPRD is
known to be similar to that in a nationally-representative
survey (Health Survey for England) [47], we expect that the
proportion of unmeasured CKD is small in CPRD and people
Figure 2
Adjusted rates and rate difference (between period with and without selective serotonin reuptake inhibitor prescription) for the ﬁrst hospitaliza-
tion due to gastrointestinal bleeding among patients with different levels of kidney function. CKD = chronic kidney disease, CI = conﬁdence
interval, GI = gastrointestinal, SSRI = selective serotonin reuptake inhibitor
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without creatinine tests are unlikely to have CKD. It would
have been inappropriate for us to use a comparison group
sampled from people with creatinine testing in CPRD, be-
cause those with creatinine testing are a less healthy group
of individuals who were not representative of the general
population [48]. Secondly, consistent with a recent US study
[3], our outcome deﬁnition was based on hospitalization re-
corded in linked hospital inpatient data, because the timing
of GI bleeding recorded in HES is likely to be more accurate
than that recorded in CPRD [49]. Moreover, we expect that
hospitalization recorded with a primary diagnosis of GI
bleeding will capture most severe cases. However, we lack
greater detail such as endoscopy ﬁndings and requirement
for blood transfusion. Nevertheless, we would not anticipate
that these characteristics are substantially different between
patients (or periods of time) with and without SSRI prescrip-
tion. Thirdly, we adjusted for a variety of potential con-
founders of the relationship between SSRI prescription and
GI bleeding, including demographics, socioeconomic and
smoking status, BMI, comorbidities, and prescribed drugs
[14–24]. However, confounding cannot be fully removed in
observational studies. Unmeasured confounders could
include over-the-counter aspirin and nonsteroidal anti-
inﬂammatory drugs, as well as severity of depression or anx-
iety; although to our knowledge there is no clear evidence
that mental-health conditions directly increase the risk of
GI bleeding. Fourth, we excluded patients with missing re-
cords for BMI and smoking status, prioritizing the statistical
adjustment for these important confounding factors over
maximizing the sample size. Although the proportion of pa-
tients with missing data was not large [with 8.7% of study
participants (42 375/484698)], the exclusion of these pa-
tients could affect the generalizability of our study results.
This would imply that our study ﬁndings may be limited
to people who are well monitored in primary care and thus
have had these characteristics recorded. Finally, although
the current study is one of the largest studies of the associa-
tion between SSRIs and GI bleeding to date [13], the statisti-
cal power may still be insufﬁcient in the group with the
most severely reduced kidney function (as indicated by the
wide conﬁdence intervals). Study power also made it difﬁ-
cult to draw robust conclusions from our posthoc subgroup
analyses by SSRI dose and receptor afﬁnity.
It is recommended that any increase in the absolute risk of
adverse outcomes should be taken into account in clinical
decision-making [42]. In our study, we found that at more ad-
vanced stages of CKD, a larger number of patients suffered
from GI bleeding potentially related to SSRIs. Therefore, the
balance between risks and beneﬁts of SSRI prescription may
need to be considered differently in patients with decreased
kidney function. Careful consideration of the potential risks
of GI bleeding after SSRI prescription for patients with CKD
is recommended.
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